LifeStance Health Group (LFST) Stock Price, News & Analysis

Company Overview

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

Key Stats

• Today's Range: $6.67 to $6.92
• 50-Day Range: $6.51 to $8.16
• 52-Week Range: $4.64 to $8.61
• Volume: 1.84 million shs
• Average Volume: 1.60 million shs
• Market Capitalization: $2.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.58
• Consensus Rating: Moderate Buy

LifeStance Health Group Stock Analysis - MarketRank™

LifeStance Health Group scored higher than 47% of companies evaluated by MarketBeat, and ranked 548th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LifeStance Health Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

LifeStance Health Group has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for LifeStance Health Group are expected to grow in the coming year, from ($0.18) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LifeStance Health Group is -26.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LifeStance Health Group is -26.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LifeStance Health Group has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.05% of the float of LifeStance Health Group has been sold short.

Short Interest Ratio / Days to Cover

LifeStance Health Group has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in LifeStance Health Group has recently decreased by 7.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LifeStance Health Group does not currently pay a dividend.

Dividend Growth

LifeStance Health Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.05% of the float of LifeStance Health Group has been sold short.

Short Interest Ratio / Days to Cover

LifeStance Health Group has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in LifeStance Health Group has recently decreased by 7.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.70

News Sentiment

LifeStance Health Group has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for LifeStance Health Group this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for LFST on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added LifeStance Health Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LifeStance Health Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $130,128.00 in company stock.

Percentage Held by Insiders

Only 6.60% of the stock of LifeStance Health Group is held by insiders.

Percentage Held by Institutions

85.50% of the stock of LifeStance Health Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LFST Stock Analysis - Frequently Asked Questions

How have LFST shares performed this year?

LifeStance Health Group's stock was trading at $7.37 at the beginning of the year. Since then, LFST shares have decreased by 7.2% and is now trading at $6.84.
View the best growth stocks for 2025 here.

How were LifeStance Health Group's earnings last quarter?

LifeStance Health Group, Inc. (NASDAQ:LFST) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The company's revenue for the quarter was up 18.9% on a year-over-year basis.
Read the conference call transcript.

When did LifeStance Health Group IPO?

LifeStance Health Group (LFST) raised $640 million in an initial public offering (IPO) on Thursday, June 10th 2021. The company issued 40,000,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan, Jefferies, TPG Capital BD LLC, UBS Investment Bank and William Blair acted as the underwriters for the IPO and Capital One Securities, AmeriVet, Drexel Hamilton, R. Seelaus & Co. and Siebert Williams Shank were co-managers.

Who are LifeStance Health Group's major shareholders?

Top institutional shareholders of LifeStance Health Group include Summit Global Investments (0.01%). Insiders that own company stock include Summit Partners Growth Equity, Michael K Lester, Gwen H Booth, Warren Gouk, Kevin Michael Mullins, Robert Bessler, Ryan Pardo, Danish J Qureshi, David Bourdon, Lisa K Miller, Anisha Patel-Dunn, Ann Varanakis and Paula Cipollone.
View institutional ownership trends.

How do I buy shares of LifeStance Health Group?

Shares of LFST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LifeStance Health Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LifeStance Health Group investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 4/11/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:LFST
• CIK: 1845257
• Web: www.lifestance.com
• Phone: 602-767-2100
• Fax: N/A
• Employees: 6,640
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.58
• High Stock Price Target: $10.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +25.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-186,260,000.00
• Net Margins: -7.90%
• Pretax Margin: -7.22%
• Return on Equity: -6.66%
• Return on Assets: -4.51%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 1.32
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $1.25 billion
• Price / Sales: 2.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.77 per share
• Price / Book: 1.81

Miscellaneous

• Outstanding Shares: 384,550,000
• Free Float: 357,386,000
• Market Cap: $2.63 billion
• Optionable: Optionable
• Beta: 1.30